Oncology – Page 10

Socioeconomic Disparities in Intrahepatic Cholangiocarcinoma in Sweden: Incidence, Treatment, and Survival in a Universal Healthcare Context

By MedXY 08/22/2025

A nationwide Swedish study reveals significant socioeconomic disparities in intrahepatic cholangiocarcinoma incidence, treatment access, and survival despite universal healthcare coverage, underscoring persistent health inequities linked to income.

Oncology Specialties

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications

By MedXY 08/21/2025

Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.

Allergy & Immunology news Oncology Specialties

Emerging Roles of Circular RNAs in Cancer and Immunotherapy: Mechanisms and Clinical Potential

By MedXY 08/21/2025

Circular RNAs (circRNAs) are pivotal regulators in cancer biology and immunotherapy, acting through mechanisms such as miRNA sponging, protein interactions, and translation. Their modulation of tumor immune microenvironment offers promising therapeutic avenues despite current technical challenges.

Clinical Updates Oncology Specialties

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous-Cell Carcinoma: A Review of Recent Evidence and Clinical Implications

By MedXY 08/21/2025

Adjuvant cemiplimab significantly improves disease-free survival in patients with high-risk cutaneous squamous-cell carcinoma post-surgery and radiotherapy, reducing locoregional and distant recurrences compared to placebo, with manageable toxicity.

OB/GYN & Women's Health Oncology Specialties

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY 08/21/2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

news OB/GYN & Women's Health Oncology Specialties

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

By MedXY 08/21/2025

A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especially in postmenopausal women.

Family Medicine & Nutrition news Oncology Specialties

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer: Impact on Survival Outcomes

By MedXY 08/19/2025

A 3-year structured exercise program post-adjuvant chemotherapy significantly improves disease-free and overall survival in colon cancer patients, based on the CHALLENGE phase 3 RCT involving 889 patients.

news Oncology Specialties

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Phase 3 Trial Overview and Clinical Implications

By MedXY 08/19/2025

The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.

news OB/GYN & Women's Health Oncology Specialties

Extending Endocrine Treatment Duration for Early Breast Cancer

By MedXY 08/19/2025

This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.

Family Medicine & Nutrition Gastroenterology news Oncology Specialties

Anti-Inflammatory Dietary Education Reduces Frailty in Colorectal Cancer Patients: Insights from a 12-Week Randomized Controlled Trial

By MedXY 08/18/2025

A 12-week anti-inflammatory dietary education significantly improved frailty, nutritional status, inflammatory biomarkers, and quality of life in frail colorectal cancer patients undergoing chemotherapy.

AI Clinical Updates news OB/GYN & Women's Health Oncology Radiology Specialties

Advancing Breast Cancer Detection: AI Identifies Missed Interval Cancers on Mammograms

By MedXY 08/18/2025

A recent study shows that an AI system can detect interval breast cancers missed by radiologists on mammograms, potentially improving early diagnosis and screening outcomes in women with dense breasts.

news Oncology Specialties

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial

By MedXY 08/15/2025

The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.

Clinical Updates General Surgery Oncology Specialties

Advancing Organ Preservation in Locally Advanced Rectal Cancer: Insights from the CAO/ARO/AIO-16 Phase 2 Trial

By MedXY 08/14/2025

Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.

General Surgery news Oncology Specialties

Intraoperative Indocyanine Green Fluorescence Angiography in Rectal Cancer Surgery: Insights from the IntAct Trial

By MedXY 08/14/2025

The IntAct randomized trial investigated whether intraoperative indocyanine green (ICG) fluorescence angiography reduces clinical anastomotic leaks after rectal cancer surgery, showing a trend toward leak reduction but no statistically significant benefit.

news Oncology Specialties

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY 08/13/2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safety profiles.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Insulin Resistance and Serum Thyroxine as Key Factors in Differentiated Thyroid Carcinoma and Malignant Cytology

By MedXY 08/11/2025

This study reveals that increased serum free thyroxine and insulin resistance-associated factors are linked to higher malignancy risk in thyroid nodules, suggesting a complex interplay between metabolic and hormonal factors in thyroid cancer development.

Gastroenterology news Oncology Specialties

Four Typical Early Signs of Colorectal Cancer: What to Watch For

By MedXY 08/10/2025

Colorectal cancer often shows subtle bowel changes early. Know the four warning signs—diarrhea, constipation, altered stool shape, and rectal bleeding—and when to seek screening and treatment.

Clinical Updates Infectious Diseases news Oncology Specialties

Nature: Influenza and SARS‑CoV‑2 can awaken dormant breast cancer cells and trigger lung metastasis

By MedXY 08/10/2025

A Nature paper shows influenza and SARS‑CoV‑2 lung infections can reactivate dormant disseminated breast cancer cells (DCCs) via IL‑6 and CD4+ T‑cell–mediated mechanisms, with concordant human data linking SARS‑CoV‑2 infection to higher cancer‑related mortality and pulmonary metastasis risk.

Clinical Updates news Oncology Specialties

Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study

By MedXY 08/08/2025

Savolitinib plus osimertinib showed clinically meaningful responses in patients with EGFR-mutated advanced NSCLC and high MET overexpression/amplification after progression on first-line osimertinib, offering a new targeted therapy option.

Clinical Updates news Oncology Specialties Urology

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis

By MedXY 08/08/2025

KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.